Subtype
Kidney and Ureter Neoplasm
CI-CAN-00001051Explore in graph →
Non-malignant518 active trials17 approved drugs81 evidence items
- NCIt
- C7514
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001051Explore in graph →
Clinical trials
2,409 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03141177 | A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma(CheckMate 9ER) | completed | Phase 3 | 701 | Bristol-Myers SquibbINDUSTRY | 18 | Aug 24, 2026 | clinicaltrials |
| NCT00379340 | Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor | completed | Phase 3 | 395 | Children's Oncology GroupNETWORK | 7 |
| Jul 24, 2026 |
| clinicaltrials |
| NCT00942331 | Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer | completed | Phase 3 | 506 | National Cancer Institute (NCI)NIH | 2 | Jun 24, 2026 | clinicaltrials |
| NCT00326898 | Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery(ASSURE) | completed | Phase 3 | 1,943 | National Cancer Institute (NCI)NIH | 3 | Jun 23, 2026 | clinicaltrials |
| NCT00352534 | Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor | completed | Phase 3 | 808 | Children's Oncology GroupNETWORK | 7 | Jun 3, 2026 | clinicaltrials |
| NCT00945009 | Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor | completed | Phase 3 | 249 | Children's Oncology GroupNETWORK | 6 | Jun 3, 2026 | clinicaltrials |
| NCT02231749 | Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214) | completed | Phase 3 | 1,096 | Bristol-Myers SquibbINDUSTRY | 28 | May 27, 2026 | clinicaltrials |
| NCT03260894 | Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302) | completed | Phase 3 | 129 | Incyte CorporationINDUSTRY | 20 | May 22, 2026 | clinicaltrials |
| NCT04987203 | Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma | completed | Phase 3 | 343 | AVEO Pharmaceuticals, Inc.INDUSTRY | 16 | May 8, 2026 | clinicaltrials |
| NCT03142334 | Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564) | completed | Phase 3 | 994 | Merck Sharp & Dohme LLCINDUSTRY | 21 | Mar 10, 2026 | clinicaltrials |
| NCT07413120 | Efficacy and Safety of VasoClip® vs. WeckClip® for Robotic Urologic Surgery | completed | Phase 3 | 40 | Incheon St.Mary's HospitalOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT02853331 | Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426) | completed | Phase 3 | 861 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Feb 2, 2026 | clinicaltrials |
| NCT01120249 | S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery(S0931) | completed | Phase 3 | 1,545 | SWOG Cancer Research NetworkNETWORK | 2 | Sep 16, 2025 | clinicaltrials |
| NCT00930033 | Clinical Trial to Assess the Importance of Nephrectomy(CARMENA) | completed | Phase 3 | 452 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Sep 5, 2025 | clinicaltrials |
| NCT02684006 | A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101) | completed | Phase 3 | 886 | PfizerINDUSTRY | 21 | Jul 30, 2025 | clinicaltrials |
| NCT00720941 | Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma(COMPARZ) | completed | Phase 3 | 1,110 | Novartis PharmaceuticalsINDUSTRY | 14 | Mar 30, 2025 | clinicaltrials |
| NCT06903260 | Robot-assisted Partial Nephrectomy With and Without Mixed Reality (REALITATEM Study) | completed | Phase 3 | 45 | Hospital Moinhos de VentoOTHER | 1 | Mar 30, 2025 | clinicaltrials |
| NCT03138512 | A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney(CheckMate 914) | completed | Phase 3 | 1,641 | Bristol-Myers SquibbINDUSTRY | 25 | Dec 18, 2024 | clinicaltrials |
| NCT03849118 | 89Zr-TLX250 for PET/CT Imaging of ccRCC- ZIRCON Study(89ZR-TLX250) | completed | Phase 3 | 300 | Telix Pharmaceuticals (Innovations) Pty LimitedINDUSTRY | 8 | May 17, 2024 | clinicaltrials |
| NCT00606866 | MRI Study of BAY 43-9006 in Metastatic Renal Cell Carcinoma(MRI) | completed | Phase 3 | 57 | University of ChicagoOTHER | 1 | Nov 29, 2023 | clinicaltrials |
| NCT02627963 | A Study to Compare Tivozanib Hydrochloride to Sorafenib in Participants With Refractory Advanced Renal Cell Carcinoma (RCC) | completed | Phase 3 | 350 | AVEO Pharmaceuticals, Inc.INDUSTRY | 12 | Jul 18, 2023 | clinicaltrials |
| NCT02420821 | A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma (RCC)(IMmotion151) | completed | Phase 3 | 915 | Hoffmann-La RocheINDUSTRY | 21 | Jan 30, 2023 | clinicaltrials |
| NCT01668784 | Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025) | completed | Phase 3 | 821 | Bristol-Myers SquibbINDUSTRY | 24 | Aug 9, 2022 | clinicaltrials |
| NCT00920816 | Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer | completed | Phase 3 | 492 | PfizerINDUSTRY | 14 | May 6, 2022 | clinicaltrials |
| NCT00369564 | Glutamic Acid in Reducing Nerve Damage Caused by Vincristine in Young Patients With Cancer | completed | Phase 3 | 250 | University of South FloridaOTHER | 1 | Aug 11, 2021 | clinicaltrials |
| NCT01865747 | A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma(METEOR) | completed | Phase 3 | 658 | ExelixisINDUSTRY | 26 | Apr 27, 2021 | clinicaltrials |
| NCT00002611 | Combination Chemotherapy Alone or With Radiation Therapy in Treating Children With Kidney Cancer | completed | Phase 3 | 3,031 | Children's Oncology GroupNETWORK | 7 | Feb 25, 2021 | clinicaltrials |
| NCT02793128 | The OLYMPUS Study - Optimized DeLivery of Mitomycin for Primary UTUC Study(Olympus) | completed | Phase 3 | 71 | UroGen Pharma Ltd.INDUSTRY | 2 | Dec 22, 2020 | clinicaltrials |
| NCT01235962 | A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC)(PROTECT) | completed | Phase 3 | 1,538 | Novartis PharmaceuticalsINDUSTRY | 26 | Nov 23, 2020 | clinicaltrials |
| NCT00397345 | TroVax Renal Immunotherapy Survival Trial | completed | Phase 3 | 733 | Oxford BioMedicaINDUSTRY | 10 | Oct 19, 2020 | clinicaltrials |
| NCT01076010 | An Extension Treatment Protocol for Subjects Who Have Participated in a Study of Tivozanib Versus Sorafenib in Kidney Carcinoma (Protocol AV-951-09-301). | completed | Phase 3 | 277 | AVEO Pharmaceuticals, Inc.INDUSTRY | 15 | Oct 5, 2020 | clinicaltrials |
| NCT01030783 | A Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma(TIVO-1) | completed | Phase 3 | 517 | AVEO Pharmaceuticals, Inc.INDUSTRY | 16 | Oct 28, 2019 | clinicaltrials |
| NCT00678392 | Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer | completed | Phase 3 | 723 | PfizerINDUSTRY | 22 | Jan 9, 2019 | clinicaltrials |
| NCT00087022 | Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer | completed | Phase 3 | 864 | Heidelberg Pharma AGINDUSTRY | 4 | Nov 27, 2018 | clinicaltrials |
| NCT01606787 | Mannitol Use During Partial Nephrectomy Prior to Renal Ischemia and Impact on Renal Function Outcomes | completed | Phase 3 | 210 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 15, 2018 | clinicaltrials |
| NCT00606632 | Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-Antibody | completed | Phase 3 | 226 | Heidelberg Pharma AGINDUSTRY | 1 | Oct 2, 2018 | clinicaltrials |
| NCT00375674 | A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer(S-TRAC) | completed | Phase 3 | 674 | PfizerINDUSTRY | 22 | Sep 21, 2018 | clinicaltrials |
| NCT01265810 | Caphosol in Oral Mucositis Due to Targeted Therapy(COMTT) | completed | Phase 3 | 64 | Impaqtt FoundationOTHER | 1 | Nov 13, 2017 | clinicaltrials |
| NCT01265901 | IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma | completed | Phase 3 | 339 | Immatics Biotechnologies GmbHINDUSTRY | 11 | Oct 12, 2017 | clinicaltrials |
| NCT02883153 | Zirconium-89-girentuximab PET/CT Imaging in Renal Cell Carcinoma | completed | Phase 2 / Phase 3 | 30 | Radboud University Medical CenterOTHER | 1 | Jun 19, 2017 | clinicaltrials |
| NCT01613846 | Phase III Sequential Open-label Study to Evaluate the Efficacy and Safety of Sorafenib Followed by Pazopanib Versus Pazopanib Followed by Sorafenib in the Treatment of Advanced / Metastatic Renal Cell Carcinoma (SWITCH-II) | completed | Phase 3 | 544 | Technical University of MunichOTHER | 3 | Apr 20, 2017 | clinicaltrials |
| NCT01064310 | Patient Preference Study of Pazopanib Versus Sunitinib in Advanced or Metastatic Kidney Cancer(PISCES) | completed | Phase 3 | 169 | Novartis PharmaceuticalsINDUSTRY | 5 | Apr 17, 2017 | clinicaltrials |
| NCT02829775 | A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical Studies | completed | Phase 2 / Phase 3 | 9 | Hoffmann-La RocheINDUSTRY | 7 | Jan 9, 2017 | clinicaltrials |
| NCT00003126 | Interleukin-2 in Treating Patients With Stage III or Stage IV Kidney Cancer | completed | Phase 3 | 69 | Loyola UniversityOTHER | 1 | Jan 4, 2017 | clinicaltrials |
| NCT00072046 | Interferon Alfa-2b With or Without Bevacizumab in Treating Patients With Advanced Renal Cell Carcinoma (Kidney Cancer) | completed | Phase 3 | 732 | Alliance for Clinical Trials in OncologyOTHER | 2 | Jul 6, 2016 | clinicaltrials |
| NCT00738530 | A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy | completed | Phase 3 | 649 | Hoffmann-La RocheINDUSTRY | 18 | Jun 23, 2016 | clinicaltrials |
| NCT00631371 | Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects(INTORACT) | completed | Phase 3 | 791 | PfizerINDUSTRY | 30 | Apr 27, 2016 | clinicaltrials |
| NCT00334282 | Safety and Efficacy of GW786034 (Pazopanib) In Metastatic Renal Cell Carcinoma | completed | Phase 3 | 435 | GlaxoSmithKlineINDUSTRY | 25 | Feb 5, 2016 | clinicaltrials |
| NCT01223027 | Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma | completed | Phase 3 | 564 | Novartis PharmaceuticalsINDUSTRY | 27 | Dec 7, 2015 | clinicaltrials |
| NCT00420888 | ABR-217620/Naptumomab Estafenatox With Interferon-alpha (IFN-alpha) Compared to IFN-alpha Alone in Patients With Advanced Renal Cell Carcinoma | completed | Phase 2 / Phase 3 | 526 | Active Biotech ABINDUSTRY | 5 | Jul 22, 2015 | clinicaltrials |
Data updated 22 days agoSource updated Aug 24, 2026source: clinicaltrials